Stock Update (NYSE:PFE): Drug Manufacturers – Major Stocks on our Scanner — Pfizer, AbbVie, Merck, and Johnson & Johnson

[Accesswire] – NEW YORK, NY / ACCESSWIRE / January 25, 2016 / Park Lane Advisor has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Merck & Company Inc. (NASDAQ: MRK), … Read more on this. Pfizer Inc. (PFE) , currently valued at $189.62B, began trading this morning at $30.83. Shares have traded today between $30.51 and $30.91 per share and has traded between $28.47 and $36.46 over the past year. PFE shares are currently priced at 14.03x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -2.14x earnings multiple. And for income investors, the company pays shareholders $1.20 per share annually in dividends, yielding 3.91%. According to a consensus of 18 analysts, the earnings estimate of $0.52 per share would be $0.02 worse than the year-ago quarter and a $0.00 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $2.18, which would be a $0.08 worse when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $13.56 Billion. If reported, that would be a 3.43% increase over the year-ago quarter. More recently, Sun Trust Rbsn Humphrey upgraded PFE from Reduce to Neutral (Nov 25, 2015). Previously, Morgan Stanley upgraded PFE from Equal-Weight to Overweight. When considering if the stock is under or overvalued, the average price target is $40.19, which is 30.36% above where the stock opened this morning. See more in (NYSE:PFE) Similar Articles: Company Update: Pfizer Inc (NYSE:PFE) – Corrected-Merck KGaA says avelumab alliance with Pfizer on track Company Update: Pfizer Inc (NYSE:PFE) – Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder Stock Update (NYSE:PFE): Britain raps Pfizer over inflated epilepsy drug prices